Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of carelizumab combined with regorafenib in
second-line treatment for patients with primary hepatocellular carcinoma.